Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. reports news about its life sciences automation business for microbial quality-control testing in healthcare manufacturing. The company develops and sells the Growth Direct platform, proprietary consumables, LIMS connectivity, software and services used to automate microbial analysis for pharmaceuticals, medical devices and personal care products.
Recurring updates include financial results and guidance, Growth Direct system placements and validations, customer orders from global biopharma and CDMO manufacturers, and company participation in healthcare investor conferences. News also covers equity compensation actions and Nasdaq-related employment inducement grants tied to its public-company governance.
Rapid Micro Biosystems (RPID) plans to participate in three investor conferences in September 2026, including Lake Street’s 10th Annual Best Ideas Growth Conference, the Sidoti Small-Cap Virtual Conference and the 5th Annual Roth Healthcare Opportunities Conference.
The company will hold one-on-one investor meetings at the Lake Street and Roth events in New York and present at 10:45 a.m. Eastern Time at the Sidoti virtual conference, which will be webcast live and archived on its investor relations website.
Rapid Micro Biosystems (Nasdaq: RPID) reported second quarter 2026 revenue of $8.1 million, up 10.9% from $7.3 million a year earlier. Product revenue rose to $5.3 million and service revenue to $2.8 million. Recurring revenue increased 14.3% to $5.0 million and represented 63% of total revenue, with consumable revenue growing more than 20% year over year.
The company achieved a record second-quarter gross margin of 15.0%, or $1.2 million, versus 3.8% in 2025, as total cost of revenue declined 2.1% to $6.8 million. Rapid Micro Biosystems placed four new Growth Direct systems, completed nine validations, and reached its 200th system placed globally. Net loss was $12.9 million, or $0.27 per share, and non-GAAP adjusted EBITDA loss was $10.3 million. Cash, cash equivalents and short-term investments totaled approximately $20.1 million at June 30, 2026. The company reaffirmed 2026 revenue guidance of $37.0–$41.0 million, gross margin of about 20%, and raised system validation guidance to at least 27.
Rapid Micro Biosystems (Nasdaq: RPID) granted, on August 3, 2026, 90,000 RSUs and a non-qualified stock option for 170,000 shares of Class A common stock as a material inducement for a new employee. The awards were issued under the company’s Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with the option priced at $2.12 per share and subject to time-based vesting over three and four years, contingent on continued employment.
Rapid Micro Biosystems (Nasdaq: RPID) will release its second quarter 2026 financial results before the market opens on Friday, August 7, 2026. Management will host a webcast conference call at 8:30 a.m. ET, accessible via live audio webcast on the company’s website, with a replay available afterward.
Rapid Micro Biosystems (Nasdaq: RPID) reported an inducement equity grant tied to a new hire. On June 3, 2026, the company granted 60,000 RSUs of Class A common stock under its Inducement Plan, approved in line with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in three equal annual installments over three years, contingent on continued employment.
Rapid Micro Biosystems (Nasdaq: RPID) priced an underwritten offering of 3,581,000 Class A shares plus warrants, and up to 1,463,000 pre-funded warrants, alongside a concurrent registered direct sale of 71,607 shares to officers and directors.
Gross proceeds are expected to be about $9.8 million, with up to an additional $21.7 million possible if all pre-funded, Series A and Series B warrants are exercised in cash.
Rapid Micro Biosystems (Nasdaq: RPID) reported first quarter 2026 revenue of $8.0 million, up 11.1% year-over-year, with recurring revenue of $5.1 million, or 63% of total. The company placed six new Growth Direct systems and completed five validations.
Product revenue grew 36% while service revenue declined 21.9%. Gross margin was 4.6%, with product and consumable gross margin percentages improving by 15 and 33 points, respectively. Net loss widened to $14.3 million ($0.31 per share). The company advanced its MilliporeSigma collaboration and reaffirmed 2026 guidance of $37.0–$41.0 million in revenue, 30–38 system placements, and gross margin of about 20%.
Rapid Micro Biosystems (Nasdaq: RPID) will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026. Management will host a live webcast conference call at 4:30 p.m. ET the same day. The live audio webcast is available on the company website and will be archived for replay.
Rapid Micro Biosystems (Nasdaq: RPID) reported record Q4 2025 revenue of $11.3M (+37% YoY) and full year 2025 revenue of $33.6M (+20% YoY). The company placed 28 Growth Direct systems in 2025 and now has 190 cumulative placements with 155 validated.
Net loss was $47.1M for 2025 and cash plus short-term investments totaled $39.0M. For 2026 the company forecasts revenue of $37.0M–$41.0M, 30–38 system placements, and gross margins of ~20%.
Rapid Micro Biosystems (Nasdaq: RPID) announced a follow-on multi-system order from Samsung Biologics on March 12, 2026 to expand deployment of the Growth Direct platform.
The order strengthens the companies' partnership and supports Samsung's expansion of automated microbial quality control across its manufacturing network, aiming for faster results, greater accuracy, and improved data integrity.